SURMOUNT-1: Tirzepatide Achieves Up to 20.9% Weight Loss in Phase 3 Obesity Trial
In the SURMOUNT-1 phase 3 trial, the dual GIP/GLP-1 receptor agonist tirzepatide produced dose-dependent weight reductions of up to 20.9% over 72 weeks in adults with obesity or overweight without diabetes — results that set a new benchmark for obesity pharmacotherapy.
What the researchers did
SURMOUNT-1 tested tirzepatide — a single molecule that activates both the GIP and GLP-1 receptors — as a treatment for obesity in people without diabetes. Tirzepatide was already approved for type 2 diabetes at the time, but SURMOUNT-1 was the first phase 3 readout dedicated to chronic weight management. The multinational trial randomized 2,539 adults with a BMI of 30 or higher, or 27 or higher with at least one weight-related complication such as hypertension, dyslipidemia, or obstructive sleep apnea. Mean baseline body weight was about 105 kg and mean BMI about 38.
Participants received tirzepatide at 5, 10, or 15 mg or placebo once weekly for 72 weeks, with doses escalated gradually in four-week steps. All groups also received lifestyle counseling aimed at a daily calorie deficit of roughly 500 kcal and at least 150 minutes of physical activity per week, so the drug effect was measured on top of standard behavioral support.
The co-primary endpoints were the percentage change in body weight from baseline and the proportion of participants losing at least 5% of their body weight. Key exclusions were diabetes, prior or planned bariatric surgery, and recent use of other weight-loss medications, which keeps the cohort a clean test of tirzepatide as first-line pharmacotherapy.
What they found
At 72 weeks, the mean weight change was −15.0% with 5 mg, −19.5% with 10 mg, and −20.9% with 15 mg of tirzepatide, compared with −3.1% on placebo. The response was clearly dose-dependent, and even the lowest dose far exceeded the placebo effect of diet and exercise counseling alone.
| Outcome at 72 weeks | Tirzepatide 5 mg | Tirzepatide 10 mg | Tirzepatide 15 mg | Placebo |
|---|---|---|---|---|
| Mean weight change | −15.0% | −19.5% | −20.9% | −3.1% |
| ≥5% weight loss | 85% | 89% | 91% | 35% |
| Discontinuation due to adverse events | 4.3% | 7.1% | 6.2% | 2.6% |
Between 85% and 91% of participants on tirzepatide lost at least 5% of their body weight, versus 35% on placebo. At the two higher doses, 50% and 57% of participants lost 20% or more — compared with 3% on placebo — a magnitude previously associated mainly with bariatric surgery. Waist circumference, blood pressure, fasting insulin, and lipid measures also improved relative to placebo, and among participants who had prediabetes at baseline, the vast majority on tirzepatide had reverted to normoglycemia by week 72.
A 20.9% mean weight reduction moves pharmacotherapy into territory that used to be reachable only through surgery — the question is no longer whether the drugs work, but how durable and tolerable they are.
For context: the placebo-adjusted difference at the highest dose was about 18 percentage points. In STEP 1, the landmark trial of semaglutide 2.4 mg for obesity, mean weight loss was 14.9% over 68 weeks — until SURMOUNT-1, the benchmark for the field. Cross-trial comparisons have obvious caveats, but tirzepatide’s 10- and 15-mg arms exceeded that mark.
The most common adverse events were gastrointestinal — nausea, diarrhea, and constipation — and occurred mainly during the dose-escalation phase. They were mostly mild to moderate in severity, and discontinuation because of adverse events ranged from 4.3% to 7.1% across tirzepatide arms versus 2.6% on placebo. Serious adverse events were infrequent and occurred at similar rates across groups.
Limitations
The trial was funded and conducted by the manufacturer, Eli Lilly, and company employees were involved in the design, analysis, and writing. That is standard for registrational trials but worth stating plainly.
The study population was predominantly female (about two-thirds) and largely white, and it excluded people with diabetes. Results therefore cannot simply be transferred to other groups. Weight loss under trial conditions — with regular contact, lifestyle support, and free medication — may also exceed what is seen in routine care.
Finally, 72 weeks is long by trial standards but short relative to a chronic disease. SURMOUNT-1 does not answer what happens after stopping; the subsequent SURMOUNT-4 withdrawal trial showed that participants who switched to placebo regained a substantial share of the lost weight, underscoring that obesity pharmacotherapy is likely a long-term commitment.
SURMOUNT-1 formed the basis of tirzepatide’s regulatory path in weight management: in November 2023, the FDA approved the drug (as Zepbound) for chronic weight management in adults with obesity, or with overweight plus at least one weight-related condition. Whether tirzepatide is appropriate in an individual case remains a decision for a physician, not for an article.